{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:50:36Z","timestamp":1784159436635,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005721","name":"Universit\u00e4t Bielefeld","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Popul Health Metrics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim is to estimate age- and sex-specific direct medical costs related to diagnosed type 1 and type 2 diabetes in Germany between 2010 and 2040.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Based on nationwide representative epidemiological routine data from 2010 from the statutory health insurance in Germany (almost 80% of the population\u2019s insurance) we projected age- and sex-specific healthcare expenses for type 1 and 2 diabetes considering future demographic, disease-specific and cost trends. We combine per capita healthcare cost data (obtained from aggregated claims data from an almost 7% random sample of all German people with statutory health insurance) together with the demographic structure of the German population (obtained from the Federal Statictical Office), diabetes prevalence, incidence and mortality. Direct per capita costs, total annual costs, cost ratios for people with versus without diabetes and attributable costs were estimated. The source code for running the analysis is publicly available in the open-access repository Zenodo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 2010, total healthcare costs amounted to more than \u20ac1\u00a0billion for type 1 and \u20ac28\u00a0billion for type 2 diabetes. Depending on the scenario, total annual expenses were projected to rise remarkably until 2040 compared to 2010, by 1\u2013281% for type 1 (\u20ac1 to \u20ac4\u00a0billion) and by 8\u2013364% for type 2 diabetes (\u20ac30 to \u20ac131\u00a0billion). In a relatively probable scenario total costs amount to about \u20ac2 and \u20ac79\u00a0billion for type 1 and type 2 diabetes in 2040, respectively. Depending on annual cost growth (1% p.a. as realistic scenario vs. 5% p.a. as very extreme setting), we estimated annual per capita costs of \u20ac6,581 to \u20ac12,057 for type 1 and \u20ac5,245 to \u20ac8,999 for type 2 diabetes in 2040.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Diabetes imposes a large economic burden on Germany which is projected to increase substantially until 2040. Temporal trends in the incidence and cost growth are main drivers of this increase. This highlight the need for urgent action to prepare for the potential development and mitigate its consequences.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12963-024-00337-x","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:02:02Z","timestamp":1721329322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Projecting the economic burden of type 1 and type 2 diabetes mellitus in Germany from 2010 until 2040"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-7144","authenticated-orcid":false,"given":"Dina","family":"Voeltz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Vetterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-4024","authenticated-orcid":false,"given":"Esther","family":"Seidel-Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-6592","authenticated-orcid":false,"given":"Ralph","family":"Brinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-4212","authenticated-orcid":false,"given":"Thadd\u00e4us","family":"T\u00f6nnies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0241-9951","authenticated-orcid":false,"given":"Annika","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/20009666.2020.1791027","volume":"10","author":"M Zilbermint","year":"2020","unstructured":"Zilbermint M. Diabetes and climate change. J Community Hosp Intern Med Perspect. 2020;10:409\u201312.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"337_CR2","doi-asserted-by":"crossref","unstructured":"Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010;87:293\u2013301.","DOI":"10.1016\/j.diabres.2010.01.026"},{"key":"337_CR3","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuanga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"337_CR4","doi-asserted-by":"publisher","unstructured":"Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pr. 2010;87:293\u2013301. https:\/\/doi.org\/10.1016\/j.diabres.2010.01.026","DOI":"10.1016\/j.diabres.2010.01.026"},{"key":"337_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2337\/dc17-1962","volume":"41","author":"C Bommer","year":"2018","unstructured":"Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, B\u00e4rnighausen T, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963\u201370.","journal-title":"Diabetes Care"},{"key":"337_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dme.13902","volume":"36","author":"T T\u00f6nnies","year":"2019","unstructured":"T\u00f6nnies T, R\u00f6ckl S, Hoyer A, Heidemann C, Baumert J, Du Y, Scheidt-Nave C, Brinks R. Projected number of people with diagnosed type 2 diabetes in Germany in 2040. Diabet Med. 2019;36:1217\u201325.","journal-title":"Diabet Med"},{"key":"337_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/dme.12177","volume":"30","author":"R Waldeyer","year":"2013","unstructured":"Waldeyer R, Brinks R, Rathmann W, Giani G, Icks A. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med. 2013;30:999\u20131008.","journal-title":"Diabet Med"},{"key":"337_CR8","doi-asserted-by":"publisher","first-page":"e0264739","DOI":"10.1371\/journal.pone.0264739","volume":"17","author":"D Voeltz","year":"2022","unstructured":"Voeltz D, T\u00f6nnies T, Brinks R, Hoyer A. Future prevalence of type 2 diabetes\u2014A comparative analysis of chronic disease projection methods. PLoS ONE. 2022;17:e0264739.","journal-title":"PLoS ONE"},{"key":"337_CR9","first-page":"177","volume":"113","author":"T Tamayo","year":"2016","unstructured":"Tamayo T, Brinks R, Hoyer A, Ku\u00df O, Rathmann W. The prevalence and incidence of diabetes in Germany: an analysis of statutory health insurance data on 65 million individuals from the years 2009 and 2010. Deutsches \u00c4rzteblatt International. 2016;113:177.","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"337_CR10","doi-asserted-by":"publisher","first-page":"e003156","DOI":"10.1136\/bmjdrc-2022-003156","volume":"11","author":"D Voeltz","year":"2023","unstructured":"Voeltz D, Brinks R, T\u00f6nnies T, Hoyer A. Future number of people with diagnosed type 1 diabetes in Germany until 2040: an analysis based on claims data. BMJ Open Diabetes Res Care. 2023;11:e003156.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"337_CR11","unstructured":"Federal Statistical Office of Germany. 14. Coordinated population projection. 2019. https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Population\/. Accessed 12 Apr 2023."},{"key":"337_CR12","doi-asserted-by":"publisher","first-page":"e001071","DOI":"10.1136\/bmjdrc-2019-001071","volume":"8","author":"B Carstensen","year":"2020","unstructured":"Carstensen B, R\u00f8nn PF, J\u00f8rgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. BMJ Open Diabetes Res Care. 2020;8:e001071.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"337_CR13","doi-asserted-by":"publisher","first-page":"e041508","DOI":"10.1136\/bmjopen-2020-041508","volume":"11","author":"C Schmidt","year":"2021","unstructured":"Schmidt C, Reitzle L, Heidemann C, Paprott R, Ziese T, Scheidt-Nave C, Baumert J. Excess mortality in adults with documented diabetes in Germany: routine data analysis of all insurance claims in Germany 2013-2014. BMJ open. 2021;11:e041508.","journal-title":"BMJ open"},{"key":"337_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/dme.13336","volume":"34","author":"E Jacobs","year":"2017","unstructured":"Jacobs E, Hoyer A, Brinks R, Icks A, Ku\u00df O, Rathmann W. Healthcare costs of type 2 diabetes in Germany. Diabet Med. 2017;34:855\u201361.","journal-title":"Diabet Med"},{"key":"337_CR15","unstructured":"Federal Statistical Office of Germany. 15. Coordinated population projection. 2023. https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Population\/. Accessed 12 Apr 2023."},{"key":"337_CR16","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00125-008-1156-z","volume":"51","author":"B Carstensen","year":"2008","unstructured":"Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187\u201396.","journal-title":"Diabetologia"},{"key":"337_CR17","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.8009686","author":"D Voeltz","year":"2023","unstructured":"Voeltz D. Projecting the economic burden of type 1 and type 2 diabetes mellitus in Germany from 2010 until 2040. Zenodo. 2023. https:\/\/doi.org\/10.5281\/zenodo.8009686","journal-title":"Zenodo"},{"key":"337_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tpb.2013.11.006","volume":"92","author":"R Brinks","year":"2014","unstructured":"Brinks R, Landwehr S. Age-and time-dependent model of the prevalence of non-communicable diseases and application to dementia in Germany. Theor Popul Biol. 2014;92:62\u20138.","journal-title":"Theor Popul Biol"},{"key":"337_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00103-012-1662-5","volume":"56","author":"C Heidemann","year":"2013","unstructured":"Heidemann C, Du Y, Schubert I, Rathmann W, Scheidt-Nave C. Pr\u00e4valenz und zeitliche Entwicklung Des Bekannten Diabetes mellitus. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2013;56:668\u201377. https:\/\/doi.org\/10.1007\/s00103-012-1662-5","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"337_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10198-016-0849-3","volume":"18","author":"S Neubauer","year":"2017","unstructured":"Neubauer S, Kreis K, Klora M, Zeidler J. Access, use, and challenges of claims data analyses in Germany. Eur J Health Econ. 2017;18:533\u20136. https:\/\/doi.org\/10.1007\/s10198-016-0849-3","journal-title":"Eur J Health Econ"},{"key":"337_CR21","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1007\/s00125-021-05409-3","volume":"64","author":"T T\u00f6nnies","year":"2021","unstructured":"T\u00f6nnies T, Hoyer A, Brinks R. Productivity-adjusted life years lost due to type 2 diabetes in Germany in 2020 and 2040. Diabetologia. 2021;64:1288\u201397.","journal-title":"Diabetologia"},{"key":"337_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1055\/s-0034-1375675","volume":"122","author":"I K\u00f6ster","year":"2014","unstructured":"K\u00f6ster I, Huppertz E, Hauner H, Schubert I. Costs of diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001. Exp Clin Endocrinol Diabetes. 2014;122:510\u20136.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"337_CR23","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.3389\/fendo.2022.1110373","volume":"13","author":"S Zucchini","year":"2022","unstructured":"Zucchini S. Editorial on clinical aspects of different forms of diabetes in children and adolescents. Front Endocrinol. 2022;13:3396.","journal-title":"Front Endocrinol"},{"key":"337_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","volume":"29","author":"N Hex","year":"2012","unstructured":"Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855\u201362.","journal-title":"Diabet Med"},{"key":"337_CR25","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 2021. https:\/\/www.diabetesatlas.org\/. Accessed 2 May 2023."},{"key":"337_CR26","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/bmjdrc-2015-000172","volume":"4","author":"C B\u00e4chle","year":"2016","unstructured":"B\u00e4chle C, Claessen H, Andrich S, Br\u00fcne M, Dintsios CM, Slomiany U, et al. Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall study. BMJ Open Diabetes Res Care. 2016;4:e000172.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"337_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/dme.12747","volume":"32","author":"N M\u00fcller","year":"2015","unstructured":"M\u00fcller N, Heller T, Freitag MH, Gerste B, Haupt CM, Wolf G, M\u00fcller UA. Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data. Diabet Med. 2015;32:951\u20137.","journal-title":"Diabet Med"},{"key":"337_CR28","doi-asserted-by":"publisher","first-page":"e012527","DOI":"10.1136\/bmjopen-2016-012527","volume":"6","author":"S Ulrich","year":"2016","unstructured":"Ulrich S, Holle R, Wacker M, Stark R, Icks A, Thorand B, et al. Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies. BMJ open. 2016;6:e012527.","journal-title":"BMJ open"},{"key":"337_CR29","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2337\/dc16-2099","volume":"40","author":"EK Ely","year":"2017","unstructured":"Ely EK, Gruss SM, Luman ET, Gregg EW, Ali MK, Nhim K, et al. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC\u2019s National Diabetes Prevention program. Diabetes Care. 2017;40:1331\u201341.","journal-title":"Diabetes Care"}],"container-title":["Population Health Metrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-024-00337-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12963-024-00337-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-024-00337-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:02:43Z","timestamp":1721329363000},"score":1,"resource":{"primary":{"URL":"https:\/\/pophealthmetrics.biomedcentral.com\/articles\/10.1186\/s12963-024-00337-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1186\/s12963-024-00337-x","relation":{},"ISSN":["1478-7954"],"issn-type":[{"value":"1478-7954","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}